# A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

> **NCT04693195** · PHASE2 · COMPLETED · sponsor: **Bellus Health Inc. - a GSK company** · enrollment: 142 (actual)

## Conditions studied

- Chronic Pruritus
- Atopic Dermatitis

## Interventions

- **DRUG:** BLU-5937
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04693195
- **Lead sponsor:** Bellus Health Inc. - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-09
- **Primary completion:** 2021-10-04
- **Final completion:** 2021-10-12
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2022-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04693195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04693195, "A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04693195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*